SCHEMBL24588682

SCHEMBL24588682

CCCCCN1CCC(C(=O)c2cc3ccccc3[nH]2)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.60
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
HRH4 Q9H3N8 5/20 0.51
HRH3 Q9Y5N1 2/20 0.51
DRD2 P14416 8/20 0.49
DRD3 P35462 6/20 0.49
CHRM1 P11229 1/20 0.48
KDM4E B2RXH2 3/20 0.47
HSD17B10 Q99714 2/20 0.47
AKR1C3 P42330 1/20 0.47
DRD4 P21917 3/20 0.46
HTR2A P28223 3/20 0.46
HTR1A P08908 2/20 0.46
HTR2C P28335 2/20 0.46
ALDH1A1 P00352 2/20 0.46
PMP22 Q01453 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24588687 0.81 SLC6A2 (0.44) KCNH2SLC6A2SLC6A4HRH4DRD2
SCHEMBL29744148 0.81 SLC6A2 (0.44) KCNH2SLC6A2SLC6A4HRH4DRD2
SCHEMBL602069 0.81 HRH4 (0.76) HRH4DRD2DRD3HTR1A
SCHEMBL603388 0.81 HRH4 (0.74) HRH4DRD2DRD3HTR1A
SCHEMBL602185 0.81 HRH4 (0.74) HRH4DRD2DRD3HTR1A
SCHEMBL6141991 0.81 HRH4 (0.74) HRH4DRD2DRD3HTR1A
SCHEMBL24588742 0.80 HRH4 (0.52) SLC6A2SLC6A4HRH4HRH3KDM4E
SCHEMBL24588438 0.80 DRD3 (0.56) SLC6A2SLC6A4DRD2DRD3KDM4E
SCHEMBL29744081 0.80 DRD3 (0.56) SLC6A2SLC6A4DRD2DRD3KDM4E
SCHEMBL7024844 0.78 FLT3 (0.62) HRH4HRH3KDM4EHSD17B10AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022136486-A1 CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) 2022-06-30 WO disclosed